
Claims

1. The use of daridorexant:



in free or pharmaceutically acceptable salt form;
in the manufacture of a medicament for the treatment of a sleep disorder;
wherein said medicament improves the daytime performance of the subject to whom it is administered.

2. The useaccording to claim 1, wherein said improvement of daytime performance is assessed by at least one of:

- the IDSIQ daytime alert/cognition domain score; and/or
- the IDSIQ daytime mood domain score, and/or
- the IDSIQ daytime sleepiness domain score.

3. The use of daridorexant in free or pharmaceutically acceptable salt form; in the manufacture of a medicament for the treatment of a sleep disorder;
wherein said medicament reduces daytime clinical manifestations associated with said sleep disorder.

4. The use according to claim 3, wherein said daytime clinical manifestations associated with said sleep disorder are symptoms of daytime sleepiness, especially as assessed by the IDSIQ daytime sleepiness domain score.

5. The use according to any one of claims 1 to 4, wherein said improvement of daytime performance / reduction of daytime clinical manifestations associated with said sleep disorder is expressed by subjects to whom daridorexant has been administered, wherein said subjects feel, cumulatively, less physically tired, less mentally tired, less sleepy and more energetic during the day.

6. The use according to any one of claims 1 to 5, wherein said sleep disorder is a dyssomnia or a sleep disorder associated with a general medical condition.

7. The use according to any one of claims 1 to 5, wherein said sleep disorder is an insomnia.

8. The use according to any one of claims 1 to 7, wherein said treatment of said sleep disorder results in at least one, preferably all of the following treatment effects:

- a decrease in latency to persistent sleep (LPS); and/or
- a decrease in wake time after sleep onset (WASO); and/or

- an increase in total sleep time subjectively (sTST) assessed daily by the patient.

9. The use according to any one of claims 1 to 8, wherein said medicament is intended for a subject who has been diagnosed as having difficulties with sleep onset and/or sleep maintenance.

10. The use according to any one of claims 1 to 9, wherein said medicament comprises daridorexant in free or pharmaceutically acceptable salt form in a unit dose of about 25 mg of daridorexant, or in a unit dose of about 50 mg of daridorexant.

11. The use according to any one of claims 1 to 10, wherein daridorexant is in hydrochloric acid salt form.

12. The use according to any one of claims 1 to 11, wherein said medicament is in form of a tablet; wherein said tablet is a film coated tablet comprising

- a tablet core; said tablet core comprising at least two, preferably all of the following excipients: mannitol, microcrystalline cellulose, povidone, croscarmellose sodium, silicon dioxide, and/or magnesium stearate; and
- a film coat; said film coat comprising at least two, preferably all of the following excipients: hypromellose, microcrystalline cellulose, glycerine, talc, titanium dioxide, and/or iron oxide.

13. The use according to any one of claims 1 to 12, wherein said medicament is to be administered within 1 h before bedtime, in particular within 30 min before bedtime.

14. The use according to any one of claims 1 to 13, wherein said sleep disorder is a chronic sleep disorder.

15. The use of daridorexant in free or pharmaceutically acceptable salt form in the preparation of a medicament wherein said medicament is for the treatment of daytime sleepiness in a subject, , wherein said subject has a reduction in daytime sleepiness as assessed by the IDSIQ daytime sleepiness domain score; wherein especially said subject has been diagnosed as having a sleep disorder.

16. The use of daridorexant in free or pharmaceutically acceptable salt form in the preparation of a medicament for the treatment of an insomnia wherein said medicament improves sleep and daytime functioning, wherein notably said medicament reduces daytime sleepiness as assessed by the IDSIQ daytime sleepiness domain score.